UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Short-Term Treasury ETF
VGSH
|
+$351M |
| 2 |
Cisco
CSCO
|
+$313M |
| 3 |
Coca-Cola
KO
|
+$283M |
| 4 |
Estee Lauder
EL
|
+$268M |
| 5 |
TUYA
Tuya Inc
TUYA
|
+$195M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.16B |
| 2 |
TAL Education Group
TAL
|
+$1.92B |
| 3 |
Alibaba
BABA
|
+$1.88B |
| 4 |
Procter & Gamble
PG
|
+$640M |
| 5 |
New Oriental
EDU
|
+$454M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.72% |
| 2 | Healthcare | 12.81% |
| 3 | Financials | 12.8% |
| 4 | Consumer Discretionary | 12.5% |
| 5 | Communication Services | 10.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRTV
2301
DELISTED
VERITIV CORPORATION
VRTV
| $764K | ﹤0.01% |
+12,440
| New | +$650K |
|
2302
Cass Information Systems
CASS
$743M
| $764K | ﹤0.01% |
18,740
+841
| +5% | +$37.9K |
|
|
HEXO
2303
DELISTED
HEXO Corp. Common Shares
HEXO
| $762K | ﹤0.01% |
+9,357
| New | +$815K |
|
2304
Banc of California
BANC
$2.97B
| $758K | ﹤0.01% |
43,232
+9,122
| +27% | +$163K |
|
2305
Agilysys
AGYS
$3.06B
| $757K | ﹤0.01% |
13,318
+1,506
| +13% | +$77.9K |
|
|
KBAL
2306
DELISTED
Kimball International
KBAL
| $756K | ﹤0.01% |
57,522
+1,947
| +4% | +$26.5K |
|
2307
Standard BioTools
LAB
$314M
| $756K | ﹤0.01% |
122,719
+15,819
| +15% | +$84.6K |
|
2308
Tucows
TCX
$175M
| $755K | ﹤0.01% |
9,400
+646
| +7% | +$51.2K |
|
2309
Akebia Therapeutics
AKBA
$252M
| $753K | ﹤0.01% |
198,740
+105,322
| +113% | +$355K |
|
2310
HealthStream
HSTM
$840M
| $750K | ﹤0.01% |
26,858
+1,887
| +8% | +$47.5K |
|
|
TRST
2311
Trustco Bank Corp NY
TRST
$938M
| $750K | ﹤0.01% |
21,809
+1,196
| +6% | +$44.3K |
|
2312
Donnelley Financial Solutions
DFIN
$1.16B
| $749K | ﹤0.01% |
+22,702
| New | +$676K |
|
2313
Energy Recovery
ERII
$443M
| $747K | ﹤0.01% |
32,770
-3,600
| -10% | -$71K |
|
2314
Ranpak Holdings
PACK
$473M
| $743K | ﹤0.01% |
29,671
+5,371
| +22% | +$113K |
|
|
GOOD
2315
Gladstone Commercial Corp
GOOD
$627M
| $741K | ﹤0.01% |
32,845
+3,407
| +12% | +$72.8K |
|
|
CLVS
2316
DELISTED
Clovis Oncology, Inc.
CLVS
| $739K | ﹤0.01% |
127,366
+50,162
| +65% | +$294K |
|
|
MYOV
2317
DELISTED
Myovant Sciences Ltd.
MYOV
| $739K | ﹤0.01% |
32,442
+2,812
| +9% | +$59.2K |
|
|
CMRX
2318
DELISTED
Chimerix, Inc.
CMRX
| $738K | ﹤0.01% |
+92,294
| New | +$767K |
|
|
OSG
2319
Octave Specialty Group
OSG
$222M
| $737K | ﹤0.01% |
47,069
+3,469
| +8% | +$55.8K |
|
2320
Central Pacific Financial
CPF
$1B
| $737K | ﹤0.01% |
28,273
+2,580
| +10% | +$70.8K |
|
2321
Alaunos Therapeutics
TCRT
$4.86M
| $734K | ﹤0.01% |
1,853
+334
| +22% | +$156K |
|
2322
Syndax Pharmaceuticals
SNDX
$1.82B
| $733K | ﹤0.01% |
42,672
+4,285
| +11% | +$78.5K |
|
2323
Tactile Systems Technology
TCMD
$665M
| $731K | ﹤0.01% |
14,067
+1,304
| +10% | +$70.5K |
|
2324
A10 Networks
ATEN
$1.95B
| $730K | ﹤0.01% |
64,796
+2,179
| +3% | +$21.1K |
|
|
CIVI
2325
DELISTED
Civitas Resources
CIVI
| $729K | ﹤0.01% |
15,480
+1,633
| +12% | +$66.3K |
|
Similar funds
UBS AM's Q2 2021 Portfolio in Review
As of Q2 2021, UBS AM held 2,827 positions worth $234B, up 3.3% from $226B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
UBS AM withdrew a net $11.4B in Q2 2021, closing 76 positions and reducing 923 holdings. Its most notable exit was Seagate, an estimated $107M position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 25% a quarter earlier, followed by Healthcare and Financials.
Against the trend, UBS AM opened a new position in Vanguard Short-Term Treasury ETF worth $350M.
- UBS AM's largest Q2 2021 buy was Vanguard Short-Term Treasury ETF: 5,703,693 shares worth $350M.
- UBS AM added most to Cisco in Q2 2021, an estimated $313M increase.
- UBS AM's biggest Q2 2021 reduction was Microsoft, cutting an estimated $3.16B.
- UBS AM fully exited Seagate in Q2 2021, selling an estimated $107M.
- UBS AM's ten largest holdings make up 21% of its $234B portfolio in Q2 2021.
- UBS AM opened 239 new positions and closed 76 in Q2 2021.
- UBS AM's portfolio value rose 3.3% quarter-over-quarter to $234B.
Based on UBS AM's 13F filing for Q2 2021, filed 16 Aug 2021.